人端粒酶RNA的cDNA探针制备及其对胃粘膜细胞端粒酶RNA表达的检测

目的 建立人端粒酶RNA表达的检测方法。方法 制备人端粒酶RNA，(human telomeraseRNA，hTR)的cDNA探针，分别应用RNA斑点杂交与端粒重复序列扩增法(TRAP)分析检测不同胃粘膜的端粒酶RNA的表达与端粒酶活性。结果 人端粒酶RNA的cDNA探针制备成功。18例活检胃癌组织及45例手术胃癌组织RNA斑点杂交检测的阳性率均为l00％，相应TRAP分析的阳性率分别为88．89％、86．67％，低于RNA斑点杂交(P＜0．05)。同时RNA斑点杂交结果提示在非癌胃组织中随着肠化程度增高人端粒酶RNA表达也增强。结论 RNA斑点杂交检测人端粒酶RNA，具有高度的敏感性和特异性，弥补了TRAP分析敏感性不足的缺点。     

SPARC, an extracellular matrix glycoprotein containing the follistatin module, is expressed by astrocytes in synaptic enriched regions of the adult brain

Although extracellular matrix (ECM) glycoproteins play important roles in neural development, their levels are generally believed to decrease in the adult brain. Immunohistochemical analysis indicates that the anti-adhesive ECM glycoprotein SPARC/osteonectin, which contains a follistatin ‘module’, is expressed in the adult rabbit nervous system. In the cerebellum, SPARC is present in Bergmann glia, with a strong signal along their radial fibres. SPARC, while enriched in membrane fractions, is not a transmembrane protein. In the hippocampus, colocalization of SPARC is observed in cells which express the astrocytic marker GFAP. The expression of SPARC by a subset of astrocytes, particularly in synaptic enriched areas, suggests a continuing role for the ECM in the adult brain.     

Cytochrome P-45011 beta in rat brain

The presence of cytochrome P-45011 beta in rat brain was studied by immunohistochemistry using polyclonal rabbit antibodies raised against purified bovine adrenocortical P-45011 beta, which is involved in the steroid 11 beta-hydroxylation and glucocorticoid formation. The results showed that cytochrome P-45011 beta immunoreactivity is selectively localized to the tracts of myelinated fibers throughout the brain. The specificity of immunohistochemical stainings with P-45011 beta antibodies was established by control tests including nonimmune rabbit immunoglobulin Gs and P-45011 beta antibodies absorbed with purified antigen. Western immunoblots of homogenates from different brain areas with P-45011 beta antibodies, together with biochemical enzymatic assays for cytochrome P-45011 beta monooxygenase activity in these homogenates, confirmed the selective localization of this enzyme observed with immunohistochemistry. Cytochrome P-45011 beta and 11 beta-hydroxylase activity were detected in a homogenate from the cortical white matter (brain area rich in myelinated fibers) as in that from the rat adrenal, but were not detectable in a homogenate from the cerebral cortex (brain area poor in myelinated fibers). Furthermore, quantitation of the P-45011 beta bands on the immunoblots by the areal density revealed that the cortical white matter contains approximately 1.4 pmol of cytochrome P-45011 beta/mg of tissue protein, the value of which was about one sixth of the corresponding value estimated in the rat adrenal. This relatively high content of cytochrome P-45011 beta was also reflected in a relatively high level of 11 beta-hydroxylase activity measured in a homogenate of this brain area by biochemical enzymatic assays using [4-14C]-11-deoxycorticosterone.(ABSTRACT TRUNCATED AT 250 WORDS)     

Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM antibody in HTLV-I-associated myelopathy

We investigated the presence of anti-human T-lymphotropic virus type I (HTLV-I) IgM in sera and cerebrospinal fluid from patients with HTLV-I-associated myelopathy (HAM) by Western blot analysis. Analyses of 36 serum samples revealed that most patients (31/36; 86.1%) had anti-HTLV-I IgM, whereas only four of 23 (17.4%) HTLV-I carriers had it. In studies of cerebrospinal fluid, anti-HTLV-I IgM was detected in 24 of 36 (66.7%) HAM patients, whereas none was detected in nine HTLV-I carriers. The differences were statistically significant (p less than 0.01). These results suggest that persistent active replication of HTLV-I occurs in the central nervous system as well as in the peripheral blood of HAM patients, and may contribute to the development of HAM.     

识时度势保持特色力求发展--中西医合校的回顾与思考

新疆医科大学为全国第二家中西医合并院校.在新疆进行中西医合校,实属时势所使,事在必行.强弱相合,处于弱势的中医学院只有坚持相对独立,才能保证于合校后发扬中医药特色、办好中医药教育.中西医合校,给原本弱小的新疆高等中医药教育事业的发展带来了诸多可供凭借和利用的积极因素,同时也存在不少负面影响.新疆医科大学在实践中认清了中西医同校的优势与缺憾,采取扶持和爱护中医的策略,不断尝试规避冲突、化解矛盾、趋利祛弊、务期和谐,终喜事业有成,使高等中医药教育得以在新疆生存,并越过低谷,走上健康发展之路.     

Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized,double-blind pilot study

Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups.     

一种鉴别免疫筛选噬菌体克隆真、假阳性的方法

目的探讨及早鉴别用免疫学方法筛选cDNA文库得到的阳性克隆是否真实可靠的方法.方法将阳性噬菌体克隆与宿主菌按一定的比例诱导培养后,取沉淀做SDS-PAGE后行W estern b lot;同时取出一个阳性克隆进行亚克隆,直至3次亚克隆均为全部阳性.结果3次亚克隆均为全部阳性的噬菌体克隆,在W estern b lot鉴定中也呈阳性反应.结论可用W estern b lot方法来鉴别用免疫学方法筛选cDNA文库得到的阳性克隆是否真实可靠.     

Serologic evidence for human ehrlichiosis in Africa

Human ehrlichiosis is a recently recognized rickettsial disease. It is caused byEhrlichia chaffeensis, an intraleucocytic Gram-negative, obligate intracellular bacterium, grouped within the genusEhrlichiae. Most human cases of ehrlichiosis have been diagnosed in the USA. Two cases have been reported outside of the USA, one in Europe and one in Africa. From 1 January to 30 June 1992, 765 sera from blood donors or other asymptomatic subjects in 8 African countries, including Ivory Coast, Burkina Faso, Mali, Central African Republic, Angola, Zimbabwe, Mozambique and Commores Islands, were tested by indirect immunofluorescence for the presence ofE. chaffeensis antibodies. Positive sera were confirmed by Western immunoblotting. Only two of 765 sera tested were positive. One serum obtained from Burkina Faso had an IgG titer of 1:200 and one from Mozambique had an IgG titer of 1:80. Human ehrlichiosis seems to occur infrequently in Africa, although many more sera from additional African countries need to be evaluated.     

中重型β地中海贫血基因类型分析

目的 了解中间型和重型β地中海贫血基因突变类型及其相关血液，生化变化。方法 应用反向点杂交法检测16种β地贫点突变基因，常规进行血细胞分析及其他地贫筛查试验。结果 27例中重型β地贫患者中10例为纯合子，17例为双重杂合子，10例纯合子中5例CD41-42纯合子，占50%，3例TATAnt-28纯合子，占30%；CD17纯合子和IVS-nt654纯合子各1例，各占10%，17例双重杂合子中5例为IVS-nt654/CD41-42占29.4%,3例为CD17/CD41-42，占17.6%;3例为TATAnt-28/CD41-42，占17.6%;2例为βE/IVS-nt654,占11.6%;CD17/TATAnt-28,IVS-nt654/CD17,IVS-nt654/CD1-1,1CD71-72/IVS-nt654各1例，各占5.9%。27例患者血红蛋白均低于90.0g/L。平均为58.8g/L；平均MCV为65.0fl。脆性均少于60%。结论 中重型β地中海贫血基因突变类型多样，组合类型不同，临床表现轻重不一，多呈中重度贫血，血液，生化均有明显改变，多需输血维持生命，故应做好产前诊断，预防其出生。